Covid-19 and Diabetes in West of Algeria (COVIDIAB-13)

Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen

Status: Unknown

Conditions: Prevalence; Diabetes Mellitus; Risk Factors; Severe Acute Respiratory Syndrome; Patient Outcome Assessment; Coronavirus Infections

Treatments: Drug: MANAGEMENT OF COVID-19

Study type: Observational

Funder types: NETWORK; Other

Identifiers

NCT04412746

COVIDIAB-13

Details and patient eligibility

About

By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019). This exponential pandemic coronavirus infection is responsible for severe forms in 15 to 20%, for critical ill requiring ventilation in 5% and for mortality in 2%. Algeria was part of the 13 top priority countries identified by WHO based on their direct links and volume of travel to the infected provinces in China.

It is known that some predisposing conditions lead to a worse outcome with coronavirus.

In China, the overall case-fatality rate was 2.3%, but was higher in patients with diabetes (7.3%). In Italy, the most common comorbidities associated with death from COVID-19 were hypertension (73.8%) and diabetes (33.9%). The US Centers for Disease Control and Prevention suggests diabetes is the most common comorbidity in COVID-19 cases. In the largest cohort NHS England study, death from COVID-19 was strongly associated with uncontrolled diabetes (after full adjustment, HR 2.36).

The West Algerian CORODIAB-13 study aims is (1) to assess the prevalence of diabetes among hospitalized patients with Covid-19, (2) to describe the phenotypic characteristics of patients with diabetes, and (3) to identify the parameters specific to the diabetic which are associated with severe forms.

In the future, this study will provide answers for two main questions

1. Why diabetics are more at risk of developing Covid-19 infection?
2. Why diabetics are at high risk of developing severe forms?

Enrollment: 100 estimated patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients admitted in a hospital center since 1th April 2020
• Patients with COVID19 with biological proof (specific PCR) or with clinical and radiological diagnosis.
• Patient with diabetes known before the admission
• New onset diabetes discovered at admission (plasma glycaemia value strictly greater than 2 g/l at any time)

Exclusion criteria

• Pregnant
• Active Cancer
• Dementia
• Minors, adults under guardianship, protected persons
• Significant disability (The Modified Rankin Scale more than 2 prior admission)